It would also be interesting to perform kinome‐wide mRNA profiling in a wide selection of tumour or patient‐derived cells before and after inhibitor exposure, so that drug resistance signatures in addition to SGK3 can be compared and contrasted as potential guides to inform targeted therapeutics. Here, SGK3 is linked to neoplasm.